SavedAdd your journal

Journals / Turkish Journal of Hematology / 2014 / Cilt: 31 - Sayı: 4

Aplastic Anemia Associated with Oral Terbinafine: A Case Report and Review of the Literature

Oral Terbinafin İlişkili Aplastik Anemi: Bir Olgu Sunumu ve Literatür Derlemesi

Bülent KANTARCIOĞLU
HÜSEYİN KEMAL TÜRKÖZ
Güven YILMAZ
Funda Pepedil TANRIKULU
Işık Kaygusuz ATAGÜNDÜZ
Cafer ADIGÜZEL
Tülin Fıratlı TUĞLULAR
Pages
411–416
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we report a case of aplastic anemia associated with oral terbinafine use and a review of the literature on hematological toxicities associated with terbinafine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Onychomycosis (OM) is a common fungal infection of the toenails and/or fingernails that is highly prevalent in the general population and also responsible for significant morbidity.
📊
Key Findings & Data:OM is caused by dermatophytes, nondermatophytic molds, or yeast.
💡
Conclusion & Impact:Here we report a case of aplastic anemia associated with oral terbinafine use and a review of the literature on hematological toxicities associated with terbinafine.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Onychomycosis (OM) is a common fungal infection of the toenails and/or fingernails that is highly prevalent in the general population and also responsible for significant morbidity. OM is caused by dermatophytes, nondermatophytic molds, or yeast. Today systemic antifungal agents are considered as the gold standard for all types of OM. Here we report a case of aplastic anemia associated with oral terbinafine use and a review of the literature on hematological toxicities associated with terbinafine.

Özet

Onikomikoz (OM) el ve ayak tırnaklarının sık görülen fungal enfeksiyonudur. Genel toplumda prevalansı yüksek bir hastalık olması nedeniyle önemli morbiditeye yol açmaktadır. OM dermatofitler, nondermatofitik küf mantarları veya mayalar ile ortaya çıkan hastalıklardır. Günümüzde onikomikozun tedavisinde sistemik antifungal ajanlar tüm OM tiplerinde altın standart tedavi olarak kabul edilmektedir. Biz burada, oral terbinafin kullanımı sırasında gelişen bir aplastik anemi olgumuzu ve literatürde terbinafine ile ilişkilendirilmiş olan hematolojik toksisitelerin derlemesini sunuyoruz.

🔖

Cite This Article

KANTARCIOĞLU, B., TÜRKÖZ, H. K., YILMAZ, G., TANRIKULU, F. P., ATAGÜNDÜZ, I. K., ADIGÜZEL, C., TUĞLULAR, T. F. (2014). Aplastic Anemia Associated with Oral Terbinafine: A Case Report and Review of the Literature. Turkish Journal of Hematology, Cilt: 31 - Sayı: 4, 411–416. https://ajindex.com/articles/412585

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Shemer A. Update: medical treatment of onychomycosis. Dermatol Ther 2012;25:582-593
  2. Grover C, Khurana A. An update on treatment of onychomycosis. Mycoses 2012;55:541-551
  3. Van Duyn GL, Elewski BE. Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US. Mycoses 2011;54:679-685
  4. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997;133:1213-1219
  5. O'Sullivan DP, Needham CA, Bangs A, Atkin K, Kendall FD. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol 1996;42:559-565
  6. ADRAC. Terbinafine and blood dyscrasias. Aust Adverse Drug React Bull 2004;23:19
  7. Bangsgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol 2011;91:358-359
  8. Perveze Z, Johnson MW, Rubin RA, Sellers M, Zayas C, Jones JL, Cross R, Thomas K, Butler B, Shrestha R. Terbinafineinduced hepatic failure requiring liver transplantation. Liver Transpl 2007;13:162-164
  9. Pillans PI, Boyd IW. Toenails and agranulocytosis. Intern Med J 2007;37:572-575. 10.Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998;38:765-767
  10. Ornstein DL, Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. J Am Acad Dermatol 1998;39:1023-1024
  11. Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br J Dermatol 1999;140:1196-1197. 13.Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci 2001;46:1714-1716
  12. Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol 2001;45:632-634. 15.Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994;31:806
  13. Tsai HH, Lee WR, Hu CH. Isolated thrombocytopenia associated with oral terbinafine. Br J Dermatol 2002;147:627- 628. 17.Grunwald MH. Thrombocytopenia associated with oral terbinafine. Int J Dermatol 1998;37:634
  14. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology 2012;2012:292-300. 19.Guinan EC. Diagnosis and management of aplastic anemia. Hematology 2011;2011:76-81. 20.Calado RT,